Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA, United States.
Washington National Primate Research Center, Seattle, WA, United States.
Front Immunol. 2024 Oct 15;15:1460344. doi: 10.3389/fimmu.2024.1460344. eCollection 2024.
Tuberculosis (TB), caused by () is a deadly infectious disease having a major impact on global health. Using the CMV vector for development of novel vaccines is a promising new strategy that elicits strong and durable, high frequency memory T cell responses against heterologous immunogens. We conducted functional transcriptomic analysis of whole blood samples collected from cohorts of rhesus (Rh) macaques that were administered RhCMV/TB vector using a prime-boost strategy. Two modified CMV vectors were used in this study, including 68-1 RhCMV/TB-6Ag (encoding 6 protein immunogens, including Ag85A, ESAT-6, Rv3407, Rv2626, Rpf A, and Rpf D) and its attenuated variant, 68-1 RhCMV/Δpp71-TB-6Ag (a cell-to-cell spread-deficient vaccine vector lacking the Rh110 gene encoding the pp71 tegument protein). Bulk mRNA sequencing, differential gene expression, and functional enrichment analyses showed that these RhCMV/TB vaccines induce the innate and adaptive immune responses with specific transcriptomic signatures, including the IL-15-induced protective gene signature previously defined to be linked with protection against simian immunodeficiency virus (SIV) by the 68-1 RhCMV/SIV vaccine. While both vectors exhibited a transcriptomic response of the IL-15 protective signature in whole blood, we show that lack of pp71 does not maintain induction of the protective signature for the full duration of the study compared to the parental non-attenuated vector. Our observations indicate that RhCMV vector vaccines induce a transcriptomic response in whole blood that include a conserved IL-15 signature of which vector-encoded pp71 is an important component of response durability that upon future challenge may define specific vaccine protection outcomes against infection.
结核病(TB)是由()引起的,是一种致命的传染病,对全球健康有重大影响。利用 CMV 载体开发新型疫苗是一种很有前途的新策略,可以引发针对异源免疫原的强烈、持久、高频的记忆 T 细胞反应。我们对接受 RhCMV/TB 载体进行初免-加强免疫策略的恒河猴(Rh)猴队列的全血样本进行了功能转录组分析。本研究使用了两种改良的 CMV 载体,包括 68-1 RhCMV/TB-6Ag(编码 6 种蛋白免疫原,包括 Ag85A、ESAT-6、Rv3407、Rv2626、RpfA 和 RpfD)及其减毒变体 68-1 RhCMV/Δpp71-TB-6Ag(一种缺乏 Rh110 基因的细胞间传播缺陷型疫苗载体,该基因编码 pp71 被膜蛋白)。批量 mRNA 测序、差异基因表达和功能富集分析表明,这些 RhCMV/TB 疫苗通过特定的转录组特征诱导先天和适应性免疫反应,包括先前定义的与 68-1 RhCMV/SIV 疫苗预防猿猴免疫缺陷病毒(SIV)相关的 IL-15 诱导的保护性基因特征。虽然两种载体在全血中都表现出 IL-15 保护性特征的转录组反应,但我们表明,与亲本非减毒载体相比,缺乏 pp71 并不能维持保护性特征的诱导,直至研究结束。我们的观察表明,RhCMV 载体疫苗在全血中诱导的转录组反应包括一个保守的 IL-15 特征,其中载体编码的 pp71 是反应持久性的重要组成部分,在未来的()感染挑战中,可能会定义针对()感染的特定疫苗保护结果。